StartupHistory

An open directory of startups through time

Public records · dated sources
Free to read. Free to reuse.

Company records / minervaneurosciences.com

Minerva Neurosciences

Minerva Neurosciences (minervaneurosciences.com): 2 changes recorded in its website history since March 2014. Homepage last checked 6 November 2026.

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

  1. MessagingBetween and
    BeforeClinical Expertise and Patient Focus
    AfterAdvancing a new approach to schizophrenia: TARGETING NEGATIVE SYMPTOMS

    Classifier interpretation of website text.

    earlier archived pagecurrent websiteHistorical capture not publicly availableLink to observation
  2. HeadlineBetween and
    BeforeMinerva Neurosciences, Inc.
    AfterClinical Expertise and Patient Focus

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation

First recorded website

Observed 23 March 2014

Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.

How it described itself

Minerva Neurosciences, Inc.

archived pageLink to first observation

All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.

How it describes itself

Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.

  1. Seen November 2026 · 1 capture · latest observed messagingAdvancing a new approach to schizophrenia: TARGETING NEGATIVE SYMPTOMS

    Minerva Neurosciences is advancing roluperidone, a potential first-in-class treatment designed to address the negative symptoms of schizophrenia.

    This wording observed 6 November 2026.

    current websiteHistorical capture not publicly available
  2. March 2017 – July 2026 · 8 capturesClinical Expertise and Patient Focus

    Dedicated to transforming the lives of patients with central nervous system diseases through innovative solutions.

    This wording observed 16 July 2026.

    archived page
    Inspect 8 captures in this group
    • 19 March 2017 · Clinical Expertise and Patient Focus archived page
    • 1 January 2018 · Clinical Expertise and Patient Focus archived page
    • 16 July 2019 · Clinical Expertise and Patient Focus archived page
    • 23 January 2021 · Clinical Expertise and Patient Focus archived page
    • 8 August 2022 · Clinical Expertise and Patient Focus archived page
    • 3 August 2023 · Clinical Expertise and Patient Focus archived page
    • 21 January 2025 · Clinical Expertise and Patient Focus archived page
    • 16 July 2026 · Clinical Expertise and Patient Focus archived page
  3. March 2014 – July 2015 · 2 capturesMinerva Neurosciences, Inc.

    This wording observed 3 July 2015.

    archived page
    Inspect 2 captures in this group
Summary of the record · AI-written

Written by an AI model on 7 November 2026 from the dated observations above; this is not the date the changes happened; each point links to the changes it rests on.

Minerva Neurosciences highlights schizophrenia negative symptoms

Minerva Neurosciences has updated its homepage messaging to emphasize a new approach to schizophrenia focused on negative symptoms, shifting away from its earlier broad “clinical expertise and patient focus” positioning.

  • Between July 2015 and March 2017, Minerva Neurosciences changed its homepage headline from “Minerva Neurosciences, Inc.” to “Clinical Expertise and Patient Focus”. [1]
  • Between July 2026 and November 2026, Minerva Neurosciences changed its homepage headline from “Clinical Expertise and Patient Focus” to “Advancing a new approach to schizophrenia: TARGETING NEGATIVE SYMPTOMS”. [2]
  • Reading: A classifier read the latest homepage change between July 2026 and November 2026 as a repositioning toward schizophrenia and negative symptoms, which suggests a narrower focus compared with the earlier broader clinical positioning. [2][1]

Cite this record

StartupHistory, “Minerva Neurosciences” company record, https://startuphistory.org/c/minervaneurosciences.com

Machine-readable: /c/minervaneurosciences.com.json. How changes are found: method.